Clinical Trials Browser

Interventional × peginterferon alfa-2b × 90 days × Clear all

NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07553767 2026-04-28

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

Phase EARLY_PHASE1 Not yet recruiting

156 enrolled

Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular, Hepatitis B, Chronic